Otolith Labs Announces $20 Million Series A Financing by Morningside Ventures
Otolith Labs, a medical technology company developing noninvasive wearable medical devices for the treatment of vestibular disorders, today announced the closing of a $20 million Series A financing round by Morningside Ventures. Building on prior investments from businessman Mark Cuban and leading ENT physicians, the proceeds will be used to support the company’s ongoing clinical programs, anticipated FDA approval and first commercial launch of a prescription wearable device using its noninvasive Vestibular System Masking (nVSM) technology for the treatment of chronic vertigo.
In The News
Otolith Receives ISO 13485 Certification for Medical Devices Quality Management Systems from BSI
This is an important milestone for medical device companies.
Mark Cuban-Backed Otolith Labs Just Raised Another $20M
Technical.ly interviews Otolith’s CEO Sam Owen about the pressing need for a new treatment option for chronic vertigo.
Otolith Presents at Auditory & Vestibular Translational Research Day
Otolith’s Chief Science Officier, Didier Depireux, Ph. D, presented on Otolith’s novel vertigo device.
Increased Bone Conducted Vibration Reduces Motion Sickness
Results from a study testing bone conductive vibrations proved the device decreases nausea from motion sickness.
Otolith Receives Breakthrough Device Designation from FDA
Otolith Labs announces closing of $3.3 Million in seed funding, as well as receiving “Breakthrough Device” Designation from FDA.
Business Insider Interviews Otolith CEO Sam Owen About Series A Financing
Otolith’s CEO Sam Owen sat down with Insider to discuss Otolith’s $20 million Series A financing.
Selected as Top Five Finalist for the MedTech Innovator Execution Award Competition
The selection was made during the pre-conference virtual live stream on September 22, 2021.
D.C. Biotech is Raising Millions to Advance Medical Device for Vertigo
CEO Sam Owen discusses Otolith Labs usage of investor funding and the companies journey the past few years.
Deals Of The Week: Otolith Raised $20 Million In Series A Financing Round
Forbes features Otolith Labs’ $20 million Series A financing in “Deals Of The Week” for the week of Sept. 7, 2022.
Otolith Labs Finds Footing With $20M For Vertigo-Treating Wearable
Fierce Medtech discusses Otolith Labs’ Series A financing and the clinical development of Otolith technology.
MedTech Innovator Selects Otolith in Top 50 Medtech Startups
MedTech innovator unveils top 50 medtech startups selected for Annual showcase and accelerator, which includes Otolith Labs.
Selected in 101 Best Washington Based Medical Device Startups
Otolith Labs selected as one of 101 top Washington based Medical Device companies by The Startup Pill.
NASA iTech 2020 Cycle 1 Winner
Through NASA’s iTech initiative, the agency discovers and assesses technologies that could help it accomplish future missions. Otolith Labs was one of the three winning teams in 2020.
Otolith Labs is Proud to Sponsor VeDa
The Vestibular Disorder Association provides educational and support resources to people suffering from chronic vertigo and vestibular disorders.
Otolith Labs Interviewed on This Week In Hearing Episode
Dr. Robert Traynor interviews Otolith CEO and CSO on This Week In Hearing, presented by Hearing Health & Technology Matters.
Development of Therapeutic Headband for Vertigo Sufferers
Washington Business Journal talks about Otolith Labs plan for FDA approval and the funding neccesary.